Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label safety study of MEDI3250 in healthy Japanese children aged 2 to 6 years
2014-003401-15Phase 3
- Sponsor
- AstraZeneca
- Start
- Mar 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of quadrivalent live attenuated influenza vaccine in influenza, sponsored by AstraZeneca. Primary endpoint: Solicited symptoms after vaccination.
02
Drugs
quadrivalent live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2014-003401-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003401-15.